報價延遲最少15分鐘:2025/05/10 05:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.79 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.51/-0.61
|
|
企業價值
310.35M
|
| 資產負債 |
|
每股賬面淨值
-0.61
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
57.56M
|
|
每股收益
0.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/10 05:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States. |